Merlion India fund buys into Aurobindo

The Temasek and Standard Chartered Private Equity vehicle goes long Indian biotech.

The Merlion India fund has reached an agreement to buy 3.1 million shares or 5.46% of listed Indian pharmaceutical company Aurobindo Pharma. The fund will pay Rs302 per share for a total consideration of Rs936.2 million $20.5 million. The price that Merlion is paying for the shares is in compliance with SEBI guidelines using the last two weeks average traded price, which is calculated as the average of the highlow of the last two weeks' prior to the notice of the EGM.

This is the first such investment made by the Merlion Indian fund, which was established in August this year. The fund has $100 million to invest in Indian...

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222